Physician profile
Samir Garyali
NPI 1679704605
$2,472.77
in general payments reported to CMS, 2019-2025
22 companies · $83.21 in 2025
The $83.21 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $658 · 2020: $497 · 2021: $1,015 · 2022: $138 · 2023: $66.48 · 2024: $15.23 · 2025: $83.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $164.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $468.65 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $370.38 | 2019-2023 | Lifevest |
| Janssen Pharmaceuticals, INC | $351.20 | 2019-2023 | Xarelto |
| Medtronic, INC. | $254.64 | 2021 | |
| Esperion Therapeutics, INC. | $150.00 | 2021 | |
| Astellas Pharma US INC | $118.07 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $115.72 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.40 | 2019-2020 | |
| Abbott Laboratories | $85.39 | 2019-2020 | |
| Novo Nordisk INC | $55.72 | 2021-2025 | Ozempic, Rybelsus |
| Terumo Medical Corporation | $48.39 | 2019 | |
| Boston Scientific Corporation | $45.80 | 2022 | |
| Cardiva Medical, INC. | $45.13 | 2019-2021 | |
| Chiesi USA, INC. | $44.96 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $38.67 | 2019-2025 | Camzyos |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $36.26 | 2021 | |
| Penumbra, INC. | $30.33 | 2019 | |
| Sanofi-Aventis U.S. LLC | $29.47 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.59 | 2025 | Caplyta |
| Opsens INC. | $25.54 | 2021 | |
| Angiodynamics, INC. | $19.81 | 2020 | |
| Vifor Pharma, INC. | $12.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samir Garyali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.